PCM
TMO icon

Palisade Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Palisade Capital Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.84M Buy
11,873
+1,196
+11% +$649K 0.19% 136
2025
Q4 		$6.19M Buy
10,677
+805
+8% +$455K 0.18% 139
2025
Q3 		$4.79M Hold
9,872
– – 0.13% 165
2025
Q2 		$4M Hold
9,872
– – 0.11% 182
2025
Q1 		$4.91M Buy
9,872
+100
+1% +$54.2K 0.14% 165
2024
Q4 		$5.08M Buy
9,772
+100
+1% +$55K 0.14% 163
2024
Q3 		$5.98M Buy
9,672
+92
+1% +$54.5K 0.16% 149
2024
Q2 		$5.3M Buy
9,580
+1,160
+14% +$665K 0.14% 157
2024
Q1 		$4.89M Sell
8,420
-2,045
-20% -$1.15M 0.13% 164
2023
Q4 		$5.55M Buy
10,465
+23
+0.2% +$11.1K 0.15% 162
2023
Q3 		$5.29M Sell
10,442
-300
-3% -$160K 0.15% 154
2023
Q2 		$5.6M Hold
10,742
– – 0.15% 156
2023
Q1 		$6.19M Sell
10,742
-110
-1% -$62K 0.17% 149
2022
Q4 		$5.98M Buy
10,852
+90
+0.8% +$47.7K 0.16% 165
2022
Q3 		$5.46M Hold
10,762
– – 0.15% 178
2022
Q2 		$5.85M Hold
10,762
– – 0.16% 167
2022
Q1 		$6.36M Buy
10,762
+145
+1% +$83.3K 0.15% 175
2021
Q4 		$7.08M Hold
10,617
– – 0.14% 178
2021
Q3 		$6.07M Buy
10,617
+1,467
+16% +$805K 0.13% 187
2021
Q2 		$4.62M Buy
9,150
+2,455
+37% +$1.16M 0.1% 213
2021
Q1 		$3.06M Buy
6,695
+1,550
+30% +$740K 0.07% 255
2020
Q4 		$2.4M Buy
5,145
+20
+0.4% +$9.38K 0.06% 274
2020
Q3 		$2.26M Hold
5,125
– – 0.07% 270
2020
Q2 		$1.86M Hold
5,125
– – 0.06% 278
2020
Q1 		$1.45M Buy
5,125
+1,025
+25% +$323K 0.05% 292
2019
Q4 		$1.33M Hold
4,100
– – 0.04% 321
2019
Q3 		$1.19M Hold
4,100
– – 0.04% 320
2019
Q2 		$1.2M Buy
4,100
+100
+3% +$27.5K 0.04% 326
2019
Q1 		$1.09M Buy
4,000
+50
+1% +$12.4K 0.04% 328
2018
Q4 		$884K Sell
3,950
-250
-6% -$58.7K 0.03% 345
2018
Q3 		$1.02M Buy
4,200
+50
+1% +$11.5K 0.03% 354
2018
Q2 		$860K Sell
4,150
-8,962
-68% -$1.9M 0.02% 357
2018
Q1 		$2.71M Sell
13,112
-16,715
-56% -$3.51M 0.09% 265
2017
Q4 		$5.66M Sell
29,827
-225
-0.7% -$43.1K 0.19% 170
2017
Q3 		$5.69M Buy
30,052
+12,028
+67% +$2.18M 0.2% 157
2017
Q2 		$3.15M Sell
18,024
-840
-4% -$141K 0.12% 220
2017
Q1 		$2.9M Sell
18,864
-355
-2% -$54.3K 0.11% 221
2016
Q4 		$2.71M Sell
19,219
-280
-1% -$41.3K 0.1% 224
2016
Q3 		$3.1M Sell
19,499
-380
-2% -$58.6K 0.11% 245
2016
Q2 		$2.94M Sell
19,879
-160
-0.8% -$23.6K 0.11% 277
2016
Q1 		$2.84M Buy
20,039
+14,939
+293% +$2M 0.09% 297
2015
Q4 		$723K Hold
5,100
– – 0.02% 439
2015
Q3 		$624K Sell
5,100
-650
-11% -$84.7K 0.02% 446
2015
Q2 		$746K Buy
5,750
+100
+2% +$13K 0.02% 441
2015
Q1 		$759K Buy
+5,650
New +$728K 0.02% 421

Other funds holding TMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Palisade Capital Management's TMO Position: Q1 2026 in Review

Palisade Capital Management increased its Thermo Fisher Scientific (TMO) stake by 11% in Q1 2026, buying an estimated $649K and bringing the position to 11,873 shares worth $5.84M. The position accounts for 0.19% of the portfolio, ranked #136.

Palisade Capital Management first reported a position in TMO in Q1 2015 and has held it in 45 quarters since. The position peaked at $7.08M in Q4 2021. 2,589 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Palisade Capital Management held 11,873 shares of Thermo Fisher Scientific worth $5.84M as of Q1 2026.
  • Palisade Capital Management bought 1,196 Thermo Fisher Scientific shares in Q1 2026, an estimated $649K.
  • Thermo Fisher Scientific made up 0.19% of Palisade Capital Management's portfolio in Q1 2026, its #136 holding.
  • Palisade Capital Management first reported a position in Thermo Fisher Scientific in Q1 2015 and has held it in 45 quarters since.
  • Palisade Capital Management's Thermo Fisher Scientific position peaked at $7.08M in Q4 2021.
  • 2,589 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Palisade Capital Management's 13F filing for Q1 2026, filed 15 May 2026.